CNS Oncology (Dec 2022)

Undesired impact of iron supplement on MRI assessment of post-treatment glioblastoma

  • Dahye Park,
  • Mina Lobbous,
  • Louis B Nabors,
  • James M Markert,
  • Jinsuh Kim

DOI
https://doi.org/10.2217/cns-2021-0018
Journal volume & issue
Vol. 11, no. 4

Abstract

Read online

Glioblastoma (GBM) is the most common malignant adult brain and has a poor prognosis. Routine post-treatment MRI evaluations are required to assess treatment response and disease progression. We present a case of an 83-year-old female who underwent MRI assessment of post-treatment GBM after intravenous iron replacement therapy, ferumoxytol. The brain MRI revealed unintended alteration of MRI signal characteristics from the iron containing agent which confounded diagnostic interpretation and subsequently, the treatment planning. Ferumoxytol injection prior to contrast enhanced MRI must be screened in post-treatment GBM patients to accurately evaluate tumor activity.

Keywords